Viral Vector Purification - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB509243830

Publication Date:

September 3, 2024

Pages:

115

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

IT Services [2]

Computing & Electronics [3]

Description:

Viral vector is a tool that molecular biologists use to deliver genetic material into cells.This process is performed usingviruses as vectors of the genetic material to be transferred into host cells. The delivery of genes by a vector is calledtransduction while the host cells are called transduced after an infection by viral vectors. Viral vector purification is theprocess by which viral particles are isolated from the host cell in which it has grown.This is done after the process ofgene delivery in the host cell has occurred.The common methods of viral vector purfication are chromatography andcentrifugation.
The global market for Viral Vector Purification was estimated to be worth US$ 197 million in 2023 and is forecast to a readjusted size of US$ 264.4 million by 2030 with a CAGR of 4.5% during the forecast period 2024-2030
Gene therapy holds great promise for treating genetic disorders, cancer, and other diseases at the genetic level. Viral vectors, such as adeno-associated viruses (AAV) and lentiviruses, are commonly used to deliver therapeutic genes to target cells. As the field of gene therapy continues to advance and gain regulatory approval, the demand for viral vector purification technologies increases. The biopharmaceutical industry is heavily invested in researching and developing advanced therapies, including gene and cell therapies. Viral vectors are an essential component of these therapies, making their purification a critical step in the manufacturing process. The growing investments in biopharmaceutical R&D drive the demand for viral vector purification technologies that can efficiently and effectively remove impurities and contaminants. Vaccines are crucial for preventing and controlling infectious diseases. Viral vectors, such as adenoviruses and vesicular stomatitis viruses (VSV), are utilized in vaccine development to deliver antigens and stimulate an immune response. With a growing focus on vaccination programs to combat diseases like COVID-19 and emerging infectious diseases, the demand for viral vector purification technologies to produce safe and effective viral vector-based vaccines is increasing. The production of viral vectors for clinical and commercial use is subject to regulatory guidelines and quality standards set by regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These guidelines emphasize the need for robust purification processes to ensure the safety, purity, and potency of viral vectors. Adhering to these guidelines drives the adoption of viral vector purification technologies. The viral vector purification market is influenced by ongoing technological advancements in purification techniques and tools. Various chromatography, filtration, and separation techniques have been developed to effectively purify viral vectors from impurities, contaminants, and host cell components. These advancements aim to improve the recovery, purity, and scalability of viral vector purification processes, meeting the increasing demands of the industry. Collaboration between academic institutions, research organizations, and biopharmaceutical companies is driving advancements in viral vector purification. Collaborative efforts contribute to the development of innovative purification techniques and technologies, fostering the growth of the viral vector purification market. The increasing prevalence of genetic diseases globally creates a need for effective gene therapy approaches. Viral vectors are essential tools in delivering therapeutic genes to correct genetic abnormalities. As the awareness and understanding of genetic diseases grow, the demand for viral vectors and their purification technologies is expected to surge.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Viral Vector Purification, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Viral Vector Purification by region & country, by Type, and by Application.
The Viral Vector Purification market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vector Purification.
Market Segmentation
By Company
Applied Biological Materials Inc.
Creative Biolabs
Bio-Rad Laboratories, Inc.
Sirion-Biotech GmbH
Merck KGaA
FUJIFILM Diosynth Biotechnologies
Batavia BiosciencesB.v.Agilent Technologies, Inc.
ProBioGen AG
Takara Bio lnc.
Novartis
Repligen
Segment by Type:
Retroviral Vectors
Vaccine Virus
Adenoviral Vectors
Adeno-Associated Viral Vectors
Lentivirus
Others
Segment by Application
Gene Therapy
Cell Therapy
Vaccinology
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Viral Vector Purification manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Viral Vector Purification in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Viral Vector Purification in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Viral Vector Purification Product Introduction
1.2 Global Viral Vector Purification Market Size Forecast
1.3 Viral Vector Purification Market Trends & Drivers
1.3.1 Viral Vector Purification Industry Trends
1.3.2 Viral Vector Purification Market Drivers & Opportunity
1.3.3 Viral Vector Purification Market Challenges
1.3.4 Viral Vector Purification Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Viral Vector Purification Players Revenue Ranking (2023)
2.2 Global Viral Vector Purification Revenue by Company (2019-2024)
2.3 Key Companies Viral Vector Purification Manufacturing Base Distribution and Headquarters
2.4 Key Companies Viral Vector Purification Product Offered
2.5 Key Companies Time to Begin Mass Production of Viral Vector Purification
2.6 Viral Vector Purification Market Competitive Analysis
2.6.1 Viral Vector Purification Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Viral Vector Purification Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vector Purification as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Retroviral Vectors
3.1.2 Vaccine Virus
3.1.3 Adenoviral Vectors
3.1.4 Adeno-Associated Viral Vectors
3.1.5 Lentivirus
3.1.6 Others
3.2 Global Viral Vector Purification Sales Value by Type
3.2.1 Global Viral Vector Purification Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Viral Vector Purification Sales Value, by Type (2019-2030)
3.2.3 Global Viral Vector Purification Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Gene Therapy
4.1.2 Cell Therapy
4.1.3 Vaccinology
4.2 Global Viral Vector Purification Sales Value by Application
4.2.1 Global Viral Vector Purification Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Viral Vector Purification Sales Value, by Application (2019-2030)
4.2.3 Global Viral Vector Purification Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Viral Vector Purification Sales Value by Region
5.1.1 Global Viral Vector Purification Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Viral Vector Purification Sales Value by Region (2019-2024)
5.1.3 Global Viral Vector Purification Sales Value by Region (2025-2030)
5.1.4 Global Viral Vector Purification Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Viral Vector Purification Sales Value, 2019-2030
5.2.2 North America Viral Vector Purification Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Viral Vector Purification Sales Value, 2019-2030
5.3.2 Europe Viral Vector Purification Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Viral Vector Purification Sales Value, 2019-2030
5.4.2 Asia Pacific Viral Vector Purification Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Viral Vector Purification Sales Value, 2019-2030
5.5.2 South America Viral Vector Purification Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Viral Vector Purification Sales Value, 2019-2030
5.6.2 Middle East & Africa Viral Vector Purification Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Viral Vector Purification Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Viral Vector Purification Sales Value
6.3 United States
6.3.1 United States Viral Vector Purification Sales Value, 2019-2030
6.3.2 United States Viral Vector Purification Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Viral Vector Purification Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Viral Vector Purification Sales Value, 2019-2030
6.4.2 Europe Viral Vector Purification Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Viral Vector Purification Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Viral Vector Purification Sales Value, 2019-2030
6.5.2 China Viral Vector Purification Sales Value by Type (%), 2023 VS 2030
6.5.3 China Viral Vector Purification Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Viral Vector Purification Sales Value, 2019-2030
6.6.2 Japan Viral Vector Purification Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Viral Vector Purification Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Viral Vector Purification Sales Value, 2019-2030
6.7.2 South Korea Viral Vector Purification Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Viral Vector Purification Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Viral Vector Purification Sales Value, 2019-2030
6.8.2 Southeast Asia Viral Vector Purification Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Viral Vector Purification Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Viral Vector Purification Sales Value, 2019-2030
6.9.2 India Viral Vector Purification Sales Value by Type (%), 2023 VS 2030
6.9.3 India Viral Vector Purification Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Applied Biological Materials Inc.
7.1.1 Applied Biological Materials Inc. Profile
7.1.2 Applied Biological Materials Inc. Main Business
7.1.3 Applied Biological Materials Inc. Viral Vector Purification Products, Services and Solutions
7.1.4 Applied Biological Materials Inc. Viral Vector Purification Revenue (US$ Million) & (2019-2024)
7.1.5 Applied Biological Materials Inc. Recent Developments
7.2 Creative Biolabs
7.2.1 Creative Biolabs Profile
7.2.2 Creative Biolabs Main Business
7.2.3 Creative Biolabs Viral Vector Purification Products, Services and Solutions
7.2.4 Creative Biolabs Viral Vector Purification Revenue (US$ Million) & (2019-2024)
7.2.5 Creative Biolabs Recent Developments
7.3 Bio-Rad Laboratories, Inc.
7.3.1 Bio-Rad Laboratories, Inc. Profile
7.3.2 Bio-Rad Laboratories, Inc. Main Business
7.3.3 Bio-Rad Laboratories, Inc. Viral Vector Purification Products, Services and Solutions
7.3.4 Bio-Rad Laboratories, Inc. Viral Vector Purification Revenue (US$ Million) & (2019-2024)
7.3.5 Sirion-Biotech GmbH Recent Developments
7.4 Sirion-Biotech GmbH
7.4.1 Sirion-Biotech GmbH Profile
7.4.2 Sirion-Biotech GmbH Main Business
7.4.3 Sirion-Biotech GmbH Viral Vector Purification Products, Services and Solutions
7.4.4 Sirion-Biotech GmbH Viral Vector Purification Revenue (US$ Million) & (2019-2024)
7.4.5 Sirion-Biotech GmbH Recent Developments
7.5 Merck KGaA
7.5.1 Merck KGaA Profile
7.5.2 Merck KGaA Main Business
7.5.3 Merck KGaA Viral Vector Purification Products, Services and Solutions
7.5.4 Merck KGaA Viral Vector Purification Revenue (US$ Million) & (2019-2024)
7.5.5 Merck KGaA Recent Developments
7.6 FUJIFILM Diosynth Biotechnologies
7.6.1 FUJIFILM Diosynth Biotechnologies Profile
7.6.2 FUJIFILM Diosynth Biotechnologies Main Business
7.6.3 FUJIFILM Diosynth Biotechnologies Viral Vector Purification Products, Services and Solutions
7.6.4 FUJIFILM Diosynth Biotechnologies Viral Vector Purification Revenue (US$ Million) & (2019-2024)
7.6.5 FUJIFILM Diosynth Biotechnologies Recent Developments
7.7 Batavia BiosciencesB.v.Agilent Technologies, Inc.
7.7.1 Batavia BiosciencesB.v.Agilent Technologies, Inc. Profile
7.7.2 Batavia BiosciencesB.v.Agilent Technologies, Inc. Main Business
7.7.3 Batavia BiosciencesB.v.Agilent Technologies, Inc. Viral Vector Purification Products, Services and Solutions
7.7.4 Batavia BiosciencesB.v.Agilent Technologies, Inc. Viral Vector Purification Revenue (US$ Million) & (2019-2024)
7.7.5 Batavia BiosciencesB.v.Agilent Technologies, Inc. Recent Developments
7.8 ProBioGen AG
7.8.1 ProBioGen AG Profile
7.8.2 ProBioGen AG Main Business
7.8.3 ProBioGen AG Viral Vector Purification Products, Services and Solutions
7.8.4 ProBioGen AG Viral Vector Purification Revenue (US$ Million) & (2019-2024)
7.8.5 ProBioGen AG Recent Developments
7.9 Takara Bio lnc.
7.9.1 Takara Bio lnc. Profile
7.9.2 Takara Bio lnc. Main Business
7.9.3 Takara Bio lnc. Viral Vector Purification Products, Services and Solutions
7.9.4 Takara Bio lnc. Viral Vector Purification Revenue (US$ Million) & (2019-2024)
7.9.5 Takara Bio lnc. Recent Developments
7.10 Novartis
7.10.1 Novartis Profile
7.10.2 Novartis Main Business
7.10.3 Novartis Viral Vector Purification Products, Services and Solutions
7.10.4 Novartis Viral Vector Purification Revenue (US$ Million) & (2019-2024)
7.10.5 Novartis Recent Developments
7.11 Repligen
7.11.1 Repligen Profile
7.11.2 Repligen Main Business
7.11.3 Repligen Viral Vector Purification Products, Services and Solutions
7.11.4 Repligen Viral Vector Purification Revenue (US$ Million) & (2019-2024)
7.11.5 Repligen Recent Developments
8 Industry Chain Analysis
8.1 Viral Vector Purification Industrial Chain
8.2 Viral Vector Purification Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Viral Vector Purification Sales Model
8.5.2 Sales Channel
8.5.3 Viral Vector Purification Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Applied Biological Materials Inc.
Creative Biolabs
Bio-Rad Laboratories, Inc.
Sirion-Biotech GmbH
Merck KGaA
FUJIFILM Diosynth Biotechnologies
Batavia BiosciencesB.v.Agilent Technologies, Inc.
ProBioGen AG
Takara Bio lnc.
Novartis
Repligen

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂